Antengene Corporation Limited (SEHK: 6996.HK) is thrilled to announce that it will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023. Dr. Jay Mei, Antengene’s Founder, Chairman, and CEO, will be delivering the presentation at 9:30 a.m. PST in San Francisco. Antengene is a leading biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology. Join us for an exciting and informative presentation!
Antengene Corporation Limited (SEHK: 6996.HK), is a revolutionary biopharmaceutical company that is committed to developing and commercializing innovative, first-in-class and best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. With the vision of “Treating Patients Beyond Borders”, Antengene strives to make a positive difference in the lives of patients around the world.
Antengene has made remarkable progress since 2017, having developed an impressive and ever-growing portfolio of 13 clinical and preclinical assets, 10 of which are globally owned. They have secured 27 investigational new drug (IND) approvals from the U.S. and Asia, and submitted 9 new drug applications (NDAs) in multiple Asia Pacific markets. Their NDA for XPOVIO® (selinexor) has already been approved in mainland China, Taiwan, South Korea, Singapore and Australia.
We look to the future with optimism and confidence, and are committed to driving our business forward. However, our actual results and performance may differ materially from our expectations. We therefore urge you to read this article carefully and with an understanding of the risks and uncertainties that could affect our future performance. Our intentions and those of our Directors or our Company are current as of the date of this article and may be subject to change in light of future developments. For a more comprehensive look at the potential risks and uncertainties we face, please refer to the “Risk Factors” section in our periodic filings with the Hong Kong Stock Exchange and to our 2021 Annual Report for year-end December 31st.